Curetis eyes IPO to execute growth plan for for multiplex infectious disease Dx platform
This article was originally published in Clinica
Executive Summary
Heartened by the recent IPO successes of a couple of its molecular diagnostics peers, German company Curetis is now looking towards the public markets for its next round of funding.